TalShu, please pass your post along to KM asking for an explanation. If you are not comfortable with that idea, I'll copy and paste then send along to KM and copy Sarissa-Denner at the same time. Thanks
Specifically, Amarin's marketing authorization submissions for VASCEPA/VAZKEPA have been achieved in Hong Kong, Saudi Arabia, and Bahrain, and applications remain pending in a number of other markets, including Australia and New Zealand, which are continuing to advance their local procedures.
He is talking about the marketing authorization submissions have been accepted by these countries. I do not know all the specifics for "approval" but most of the countries require an intention to submit, presubmission meetings, submission of the application, validation of the application, then the assessment of the submitted application followed by a decision from the respective country. I didn't believe KM was deceiving shareholders in any way. He basically is saying our application have been successfully submitted in these countries and is actively traveling down the paths for approval or rejection whereas we are still in the process of having our applications successfully submitted and validated in other markets such as Australia and New Zealand. I was pleasantly surprised with cash burn this quarter. I expected a dip in revenue but did not expect that we would still be north of 300m with cash after Q3. UK sounds promising and they appear to be making strides ahead of what their models have shown. Have a great weekend.
TalShu, I forwarded your detailed dd to KM and Sarissa/Denner asking for clarification. Let's see how long it takes to receive a reply. LOL wishful thinking! I cc Per Wold-Olsen but his email address was incorrect. Does anyone out there know how to contact the COB???